Cancer immunotherapy, which includes adoptive cell transfer (ACT) for immune cells and monoclonal antibody (mAb) treatment, is a way to treat cancer by modifying an immune response. Immunoregulatory pathway blockage or activation, which is the basis of mAb therapy’s stimulation of T cell function, has produced notable therapeutic responses in a range of tumor types. After therapy, some individuals may not be able to sustain a robust immune response. Finding predictive biomarkers is therefore essential to choosing patients who will benefit from the treatment.
DNA Barcoding Method
The DNA barcode-based protein measurement method is perfect for detecting rare molecular tumor cells or cancer low abundance surface markers of cells because it translates protein signals into barcoded oligonucleotide probes and amplifies signals by nucleic acid amplification for ultra-sensitive detection, even detecting single-molecule levels.